N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromb

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

548341, 548336, 544139, 546210, 514326, 514240, 514397, 514399, A61K 31415, A61K 2700, A61K 31445, C07D23354

Patent

active

046020160

ABSTRACT:
N-(mono or disubstituted phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine, and the vascular complications of diabetes.

REFERENCES:
patent: 3534061 (1970-10-01), Black
patent: 4078071 (1978-03-01), Walker
Moncada et al., Prostaglandins, vol. 13, pp. 611-618 (1977).
Needleman et al., Proc. Natl. Acad. Sci., USA, vol. 74, pp. 1716-1720 (1977).
Tai et al., Biochem. Biophys. Res. Commun., vol. 80, pp. 236-242 (1978).
Yoshimoto et al., Prostaglandins, vol. 16, pp. 529-540 (1978).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromb does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromb, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromb will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-866229

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.